...
首页> 外文期刊>Journal of Medical Microbiology: An Official Journal of the Pathological Society of Great Britain and Ireland >Risk factors, outcomes and epidemiology associated with Clostridium difficile infection in patients with haematological malignancies in a tertiary care hospital in China
【24h】

Risk factors, outcomes and epidemiology associated with Clostridium difficile infection in patients with haematological malignancies in a tertiary care hospital in China

机译:中国三级医院血液系统恶性肿瘤患者难辨梭状芽胞杆菌感染的危险因素,结局和流行病学

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The purpose of this study was to evaluate the risk factors, outcomes and epidemiology associated with Clostridium difficile infection (CDI) in patients with haematological malignancies in a tertiary care hospital in China. C. difficile screening was performed on patients admitted for chemotherapy or haematopoietic stem cell transplantation between 2009 and 2013. C. difficile isolates were analysed by multilocus sequence typing, and a retrospective chart review was performed on all patients with a positive toxin assay. CDI was diagnosed in 21 haematology–oncology ward patients and 14 marrow transplantation service patients for a cumulative incidence of 1.89/1000 and 3.69/1000 patient-days, respectively. Univariate analyses showed that patients who received etoposide had an increased risk of CDI (odds ratio 4.25, 95 % confidence interval 1.32–13.64). There was only one patient death, for which CDI was not the primary cause. Ten sequence types (STs) were identified, of which ST-3 and ST-54 were the most common; the hypervirulent ST-1 (ribotype 027) and ST-11 (ribotype 078) C. difficile strains were not detected in the patients in this study. The incidence of CDI did not differ between patients receiving chemotherapy and those receiving haematopoietic stem cell transplantation. The only risk factor for chemotherapy patients was treatment with etoposide.
机译:这项研究的目的是评估中国三级医院血液系统恶性肿瘤患者与艰难梭菌感染(CDI)相关的危险因素,结果和流行病学。在2009年至2013年之间对接受化学疗法或造血干细胞移植的患者进行了艰难梭菌筛查。通过多基因座序列分型对艰难梭菌分离株进行了分析,并对所有毒素检测阳性的患者进行了回顾性图表审查。在21例血液肿瘤科病房患者和14例骨髓移植服务患者中诊断出CDI,累积发生率分别为1.89 / 1000和3.69 / 1000患者-天。单因素分析表明接受依托泊苷的患者发生CDI的风险增加(赔率4.25,95%置信区间1.32–13.64)。只有一名患者死亡,而CDI并不是主要原因。鉴定出十种序列类型(ST),其中最常见的是ST-3和ST-54。在本研究的患者中未检测到高毒力的ST-1(核型027)和ST-11(核型078)艰难梭菌菌株。接受化疗的患者和接受造血干细胞移植的患者之间的CDI发生率没有差异。化疗患者的唯一危险因素是依托泊苷治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号